Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) and Swiss firm Bioeq today announced a strategic partnership for the exclusive commercialization of Bioeq's FYB201, a biosimilar candidate to the ophthalmic drug Lucentis (ranibizumab) in Europe, Canada, Israel and New Zealand.
Lucentis is marketed by Swiss pharma giants Roche (ROG: SIX) in the USA and Novartis (NOVN: VX) elsewhere, and generated full-year 2020 revenues of $1.93 billion, down 7% year on year, for Novartis. However, first-quarter sales of the drug reached $545 million, (+12%, +4% cc), helped by a strong performance in China.
Bioeq has in-licensed the exclusive global commercialization rights to FYB201 from the German biosimilar developer Formycon AG.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze